Economic Expertise in
Across Europe and Around the World
If you have a finance, economics or statistical challenge, we have the solution.
Our consultants and experts provide in-depth analyses of issues related to mergers and acquisitions, horizontal and vertical agreements, abuse of dominance, state aid, regulation compliance, and damage claims, including collective actions and high-profile cases.
We have significant experience managing large-scale, complex litigations across all areas of finance, including valuation, securities litigation, market manipulation, and insider trading. Our global teams are drawn from across our offices in Europe, North America, and Asia.
Our experts have deep knowledge and experience in health economics and outcomes research (HEOR) topics and methodologies. We can partner with clients to support pharmaceutical products throughout their life cycles, and our economic work ranges from cost-of-illness and cost-of-adverse-events calculations to sophisticated budget models.
We provide consulting and expert testimony on a variety of topics, including the economic evaluation of government regulations in some of the largest international arbitrations to date.

Dr. Chapsal is an economist who specializes in empirical and theoretical industrial organization. He has provided economic expertise in a large number of high-profile cases involving mergers, cartels, information exchanges, abuses of dominant positions, regulation, intellectual property matters, and damages quantifications. Recent examples include the Lafarge/Holcim and Fnac/Darty mergers, as well as airfreight, cathode ray tube, and elevator cartel cases. Dr. Chapsal has also assisted various firms in designing optimized pricing strategies and dealing with policy issues. His reports have been presented to the competition authorities of France, Germany, Austria, and South Africa; the European Commission; the Higher Regional Court of Düsseldorf; and the Court of Appeals, Conseil d’Etat, Conseil constitutionnel, and Tribunal of Commerce of Paris.
Prior to joining Analysis Group, Dr. Chapsal founded MAPP, a Paris- and Brussels-based economic consultancy, which was acquired by KPMG in 2018. Previously, he worked in a US competition economics consultancy. Dr. Chapsal regularly publishes articles on competition economics, on subjects ranging from the econometric analysis of cartels to geographic market delineation and exclusionary strategies. He is an affiliated professor at the Sciences Po Department of Economics and a member of the CESifo academic research network.
Antoine Chapsal

Antoine Chapsal

Marc Van Audenrode

Chris Feige

Emmanuel Frot

Jessica Resch
Veolia/Suez Merger Approval
On behalf of Suez in its acquisition by the international environmental services conglomerate Veolia, Analysis Group teams provided economic and financial analyses for review by regulatory agencies in multiple countries.
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Journal of Clinical Oncology, 2024
Associated People

Is Data “The New Oil”? Non-Price Effects of Mergers in Data-Intensive Industries
In recent years, regulators and other interested parties have advocated for increased attention to non-price effects of mergers, particularly when data is a key input but not the main product of the merging parties.
Associated People

Steinhoff International Holdings N.V. Shareholder Litigation
Following years of negotiation, Steinhoff International Holdings N.V., received approval from courts in the Netherlands and South Africa for a €1.7 billion global settlement with shareholders and creditors.
LVMH Moet Hennessy-Louis Vuitton SE Acquisition of Tiffany & Co.
For the proposed acquisition of global luxury jeweler Tiffany & Co. by LVMH Moët Hennessy Louis Vuitton SE (LVMH), an Analysis Group team led provided economic analysis in support of securing merger approval from competition authorities across nine countries and the European Union.
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
Future Oncology, 2024
Associated People
